The RADIANCE 2 study, which studied torcetrapib in 752 patients with mixed hyperlipidemia, showed “strikingly similar results,” Dr. Kastelein said at the meeting.
Although torcetrapib led to unparalleled increases in HDL cholesterol, it failed to reduce atheroma volume. DR. NISSEN